OLIGOPROGRESSIVE METASTATIC CANCER – CONSENSUS OF MEDICAL, RADIATION, AND SURGICAL ONCOLOGISTS
This symposium will bring together leading oncologists from medical, radiation, and surgical specialties to address a critical gap in current oncology practice - how to define and manage oligoprogressive disease across tumor types. The participation of a Kazakhstan and international leaders would significantly enrich the scientific discourse and ensure the integration of local & global best practices and research perspectives.
In-person (Almaty, Academy of Science, Hall 1) and Virtual
A medical oncologist’s Perspective (15 min) - Prof. Indira Omarova, KZ
A radiation oncologist’s Perspective (15 min) - Prof. Timur Mitin, USA
Surgical metastatectomy or ablative RT for oligometastases (15 minutes) - Prof. Timur Mitin, USA
Systemic therapy – to hold, change or to continue same (15 minutes) - Dr. Ilya Tsimafeyeu, USA/Russia
Lung cancer - Dr. Dana Alisheva, KZ
GI tumors - Prof. Maia Dzhugashvili, Spain
Breast cancer - Dr. Nazgul Omarbayeva, KZ
Prostate cancer - Dr. Akmaral Savkhatova. KZ
Bladder cancer - Dr. Samat Kaldarbekov, KZ
Head & Neck tumors - Prof. Timur Mitin, USA
Moderated by Prof. Dilyara Kaidarova, KZ Prof. Timur Mitin, USA Prof.Maya Dzhugashvilli, Spain Dr. Ilya Tsimafeyeu, USA/RU
Welcome speach
Dilyara Kaidarova
Host Chair, President of the Kazakhstan Cancer Society, Academician of the National Academy of Sciences and honored professor at the Kazakh Medical University named after S. Asfendiyarov
This meeting represents not only an important step toward multidisciplinary consensus in oncology but also a highly relevant initiative for countries like Kazakhstan and the broader Central Asian region. Our institutions are increasingly confronted with cases of oligoprogression, yet there remains a striking lack of unified guidance on how best to approach these patients across disciplines and tumor types.
Timur Mitin
Chair, Professor of Radiation Oncology, Oregon Health and Science University Radiation oncologist, OHSU Knight Cancer Institute Portland
Oligoprogressive disease presents an evolving and clinically significant challenge in oncology. With advances in systemic therapies extending survival, clinicians are increasingly faced with scenarios where limited sites of progression arise amidst otherwise controlled disease. These cases demand nuanced and collaborative management strategies that integrate local and systemic treatment modalities.
Ilya Tsimafeyeu
Co-Chair, Director, Bureau for Cancer Research - BUCARE, Medical Oncologist, International clinic STOONCO
Currently, there are very few large-scale studies evaluating the efficacy of different treatment strategies for oligoprogression. It is critically important that Central Asian patients are represented in future clinical trials and real-world studies addressing this unmet need. This meeting provides a unique opportunity to set research priorities that reflect a truly global perspective, ensuring that advances in cancer care are inclusive and applicable to diverse patient populations.
Dilyara Kaidarova
Host Chair, President of the Kazakhstan Cancer Society, Academician of the National Academy of Sciences and honored professor at the Kazakh Medical University named after S. Asfendiyarov
This meeting represents not only an important step toward multidisciplinary consensus in oncology but also a highly relevant initiative for countries like Kazakhstan and the broader Central Asian region. Our institutions are increasingly confronted with cases of oligoprogression, yet there remains a striking lack of unified guidance on how best to approach these patients across disciplines and tumor types.
Timur Mitin
Chair, Professor of Radiation Oncology, Oregon Health and Science University Radiation oncologist, OHSU Knight Cancer Institute Portland
Oligoprogressive disease presents an evolving and clinically significant challenge in oncology. With advances in systemic therapies extending survival, clinicians are increasingly faced with scenarios where limited sites of progression arise amidst otherwise controlled disease. These cases demand nuanced and collaborative management strategies that integrate local and systemic treatment modalities.
Ilya Tsimafeyeu
Co-Chair, Director, Bureau for Cancer Research - BUCARE, Medical Oncologist, International clinic STOONCO
Currently, there are very few large-scale studies evaluating the efficacy of different treatment strategies for oligoprogression. It is critically important that Central Asian patients are represented in future clinical trials and real-world studies addressing this unmet need. This meeting provides a unique opportunity to set research priorities that reflect a truly global perspective, ensuring that advances in cancer care are inclusive and applicable to diverse patient populations.